{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:08:46Z","timestamp":1787497726965,"version":"build-2736575974"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>COVID-19 and autoinflammatory diseases, such as Adult-onset Still\u2019s Disease (AOSD), are characterized by hyperinflammation, in which it is observed massive production and uncontrolled secretion of pro-inflammatory cytokines. The specialized pro-resolving lipid mediators (SPMs) family is one the most important processes counteracting hyperinflammation inducing tissue repair and homeostasis restoration. Among SPMs, Protectin D1 (PD1) is able to exert antiviral features, at least in animal models. The aim of this study was to compare the transcriptome of peripheral blood mononuclear cells (PBMCs) from patients with AOSD and COVID-19 and to evaluate the role of PD1 on those diseases, especially in modulating macrophages polarization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study enrolled patients with AOSD, COVID-19, and healthy donors HDs, undergoing clinical assessment and blood sample collection. Next-generation deep sequencing was performed to identify differences in PBMCs transcripts profiles. Plasma levels of PD1 were assessed by commercial ELISA kits. Monocyte-derived macrophages were polarized into M1 and M2 phenotypes. We analyzed the effect of PD1 on macrophages differentiation. At 10 days, macrophages were analyzed for surface expression of subtypes markers by flow cytometry. Cytokines production was measured in supernatants by Bio-Plex Assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the transcriptomes from AOSD patients and COVID-19 patients, genes involved in inflammation, lipid catabolism, and monocytes activation were specifically dysregulated in AOSD and COVID-19 patients when compared to HDs. Patients affected by COVID-19, hospitalized in intensive care unit (ICU), showed higher levels of PD1 when compared to not-ICU hospitalized patients and HDs (ICU COVID-19 vs not-ICU COVID-19, p= 0.02; HDs vs ICU COVID-19, p= 0.0006). PD1 levels were increased in AOSD patients with SS \u22651 compared to patients with SS=0 (p=0.028) and HDs (p=0.048).\n                      <jats:italic>In vitro<\/jats:italic>\n                      treatment with PD1 of monocytes-derived macrophages from AOSD and COVID-19 patients induced a significant increase of M2 polarization vs control (p&amp;lt;0.05). Furthermore, a significant release of IL-10 and MIP-1\u03b2 from M2 macrophages was observed when compared to controls (p&amp;lt;0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>PD1 is able to induce pro-resolutory programs in both AOSD and COVID-19 increasing M2 polarization and inducing their activity. In particular, PD1-treated M2 macrophages from AOSD and COVID-19 patients increased the production of IL-10 and enhanced homeostatic restoration through MIP-1\u03b2 production.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1148268","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:23:54Z","timestamp":1682036634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The specialized pro-resolving lipid mediator Protectin D1 affects macrophages differentiation and activity in Adult-onset Still\u2019s disease and COVID-19, two hyperinflammatory diseases sharing similar transcriptomic profiles"],"prefix":"10.3389","volume":"14","author":[{"given":"Luca","family":"Navarini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vomero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Currado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onorina","family":"Berardicurti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Biaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Bearzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Corberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Rigon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Arcarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Leuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fogolari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Di Cola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Sambuco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Travaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Angeletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ursini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminia","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice Eugenio","family":"Agr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Iagnocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Antonelli Incalzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Maccarrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating inflammation by blocking interleukin-1 in humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Semin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/08923973.2021.1931302","article-title":"Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications","volume":"43","author":"Shawki","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720109","article-title":"Monocytes and macrophages in COVID-19","volume":"12","author":"Knoll","year":"2021","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40001-023-01072-z","article-title":"Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"28","author":"Dahms","year":"2023","journal-title":"Eur J Med Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.569849","article-title":"Autophagy modulation in lymphocytes from COVID-19 patients: New therapeutic target in SARS-COV-2 infection","volume":"11","author":"Vomero","year":"2020","journal-title":"Front Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211059598","article-title":"Update on the therapy of adult-onset still\u2019s disease with a focus on IL-1-inhibition: a systematic review","volume":"13","author":"Kedor","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset still\u2019s disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J Autoimmun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: a storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1372194","article-title":"Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets","volume":"13","author":"Ruscitti","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01130","article-title":"Severe COVID-19, another piece in the puzzle of the hyperferritinemic syndrome. an immunomodulatory perspective to alleviate the storm","volume":"11","author":"Ruscitti","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218048","article-title":"Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence\u2013radiological differences","volume":"79","author":"Ruscitti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ni1276","article-title":"Resolution of inflammation: the beginning programs the end","volume":"6","author":"Serhan","year":"2005","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.06.028","article-title":"Bioactive lipids, inflammation and chronic diseases","volume":"159","author":"Leuti","year":"2020","journal-title":"Adv Drug Delivery Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.02.027","article-title":"The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza","volume":"153","author":"Morita","year":"2013","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99888","article-title":"GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain","volume":"128","author":"Bang","year":"2018","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.06.004","article-title":"Adult-onset still\u2019s disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies","volume":"51","author":"Efthimiou","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58020144","article-title":"Cytokine storm in COVID-19: Immunopathogenesis and therapy","volume":"58","author":"Zanza","year":"2022","journal-title":"Medicina (Mex)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2020.10.e21","article-title":"Activation of inflammation and resolution pathways of lipid mediators in synovial fluid from patients with severe rheumatoid arthritis compared with severe osteoarthritis","volume":"10","author":"Sano","year":"2020","journal-title":"Asia Pac Allergy"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/all.14595","article-title":"Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19","volume":"76","author":"Andreakos","year":"2021","journal-title":"Allergy"},{"key":"B20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jaci.2018.04.004","article-title":"Dexamethasone induces \u03c93-derived immunoresolvents driving resolution of allergic airway inflammation","volume":"142","author":"Pyrillou","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170955","article-title":"Macrophage activation syndrome in patients affected by adult-onset still disease: Analysis of survival rates and predictive factors in the gruppo italiano di ricerca in reumatologia clinica e sperimentale cohort","volume":"45","author":"Ruscitti","year":"2018","journal-title":"J Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12916-016-0738-8","article-title":"Adult-onset still\u2019s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers","volume":"14","author":"Ruscitti","year":"2016","journal-title":"BMC Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult still\u2019s disease: manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Med (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26226970","article-title":"Role of specialized pro-resolving mediators in modifying host defense and decreasing bacterial virulence","volume":"26","author":"Thornton","year":"2021","journal-title":"Molecules"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953730","article-title":"Activation mechanisms of monocytes\/macrophages in adult-onset still disease","volume":"13","author":"Tsuboi","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nri.2015.4","article-title":"Specialized pro-resolving mediators: endogenous regulators of infection and inflammation","volume":"16","author":"Basil","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.7.4345","article-title":"Molecular circuits of resolution: Formation and actions of resolvins and protectins","volume":"174","author":"Bannenberg","year":"2005","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.679068","article-title":"Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis","volume":"290","author":"Poisson","year":"2015","journal-title":"J Biol Chem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.219519","article-title":"Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction","volume":"105","author":"Kooij","year":"2020","journal-title":"Haematologica"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2022.116089","article-title":"Resolution of inflammation: Intervention strategies and future applications","volume":"449","author":"Panezai","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0256226","DOI":"10.1371\/journal.pone.0256226","article-title":"Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients","volume":"16","author":"Palmas","year":"2021","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217618","article-title":"Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander","volume":"79","author":"Ruscitti","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.01.004","article-title":"Increased level of h-ferritin and its imbalance with l-ferritin, in bone marrow and liver of patients with adult onset still\u2019s disease, developing macrophage activation syndrome, correlate with the severity of the disease","volume":"14","author":"Ruscitti","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e31034","DOI":"10.7759\/cureus.31034","article-title":"Association of COVID-19 real-time reverse transcription-polymerase chain reaction (RT-PCR) cycle threshold value with surrogate markers of disease severity","volume":"14","author":"John","year":"2022","journal-title":"Cureus"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235326","article-title":"Ferritin and c-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset still\u2019s disease. analysis of the multicentre gruppo italiano di ricerca in reumatologia clinica e sperimentale (GIRRCS) cohort","volume":"15","author":"Di Benedetto","year":"2020","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6261","article-title":"Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans","volume":"369","author":"Arunachalam","year":"2020","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1683347","article-title":"The M2 macrophage marker CD206 : a novel prognostic indicator for acute myeloid leukemia","volume":"9","author":"Xu","year":"2020","journal-title":"OncoImmunology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"13129","DOI":"10.1038\/s41598-018-31565-5","article-title":"Macrophage mannose receptor, CD206, predict prognosis in patients with pulmonary tuberculosis","volume":"8","author":"Suzuki","year":"2018","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632238","article-title":"Specialized pro-resolving mediators as potential regulators of inflammatory macrophage responses in COVID-19","volume":"12","author":"Balta","year":"2021","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41598-017-00103-0","article-title":"Protectin DX increases survival in a mouse model of sepsis by ameliorating inflammation and modulating macrophage phenotype","volume":"7","author":"Xia","year":"2017","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/nqac131","article-title":"Lipid emulsion rich in n\u20133 polyunsaturated fatty acids elicits a pro-resolution lipid mediator profile in mouse tissues and in human immune cells","volume":"116","author":"Noureddine","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04642-x","article-title":"Elevated serum levels of interleukin-10 in adult-onset still\u2019s disease are associated with disease activity","volume":"38","author":"Sun","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac247","article-title":"Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset still\u2019s disease","volume":"62","author":"Ruscitti","year":"2022","journal-title":"Rheumatology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155640","article-title":"A review on the role of chemokines in the pathogenesis of systemic lupus erythematosus","volume":"146","author":"Ghafouri-Fard","year":"2021","journal-title":"Cytokine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1148268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:23:58Z","timestamp":1682036638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1148268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2023.1148268"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1148268","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1148268"}}